Comparative Pharmacology
Head-to-head clinical analysis: OXYMORPHONE HYDROCHLORIDE versus SUBLIMAZE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYMORPHONE HYDROCHLORIDE versus SUBLIMAZE PRESERVATIVE FREE.
OXYMORPHONE HYDROCHLORIDE vs SUBLIMAZE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxymorphone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception and response. It also has affinity for kappa and delta opioid receptors.
Fentanyl is a potent synthetic opioid agonist with primary action at the mu-opioid receptor. It induces analgesia, sedation, and respiratory depression by activating G-protein-coupled receptors that inhibit adenylyl cyclase, reduce cAMP production, and modulate ion channels (e.g., potassium efflux, calcium influx).
Initial: 1 mg IV/IM every 3-4 hours as needed for moderate to severe pain; titrate to effect. For patient-controlled analgesia (PCA), 0.5 mg IV loading dose, then 0.25-0.5 mg every 6-15 minutes with lockout. Rectal suppository: 5 mg every 4-6 hours.
IV: 0.5-2 mcg/kg bolus, may repeat q2-4h; or 0.5-1 mcg/kg/h infusion; IM: 0.5-2 mcg/kg q1-2h prn.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours (range 4-12 h in elderly/renal impairment). Clinically, steady-state achieved within 24-36 hours.
Terminal elimination half-life is 3-7 hours (mean 4.5 h) after IV administration, but may be prolonged (up to 12-15 h) in elderly, hepatic impairment, or after prolonged infusion due to redistribution.
Primarily renal (90% as parent drug and metabolites); <1% fecal. Unchanged oxymorphone accounts for ~30% of urinary recovery.
Primarily renal: fentanyl and its metabolites are excreted in urine (~75%) and feces (~9%). Less than 10% excreted unchanged.
Category C
Category C
Opioid Analgesic
Opioid Analgesic